Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion

被引:0
|
作者
Gebbia, V
Mauceri, G
Testa, A
Tirrito, M
Varvara, F
Cucchiara, A
Borsellino, N
Girlando, A
Ferrara, M
Caruso, F
机构
[1] Ctr Catanese Oncol, Div Med Oncol, I-95100 Catania, Italy
[2] Clin Macchiarella, Div Oncol, Palermo, Italy
[3] Clin Torina, Serv Oncol, Palermo, Italy
[4] Ctr Catanese Oncol, Div Radiotherapy, Catania, Italy
[5] Ctr Catanese Oncol, Div Surg Oncol, I-95100 Catania, Italy
关键词
breast cancer; metastases; 5-fluorouracil; levofolinic acid; vinorelbine;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-four consecutive patients with metastatic breast carcirioma (MBC) refractory to first line chemotherapy 2 were treated with high-dose folinic acid (FA) 100 mg/m(2) diluted in 250 cc of normal saline as 2 2 hour infusion followed by 5-fluorouracil (5FU) 400 mg/m(2) bolus then 5FU 600 mg/m(2) as continuous infusion for 22 hours. This therapy was repeated for 2 consecutive days. Chemotherapy was repeated every 15 days. All enrolled patients were evaluable for objective response. A complete response was achieved in 1 patient (4%) and a partial response in 6 cases (25%) for an overall response rate of 29% (confidence limits 18%-39%). The median duration of objective responses was 8.4+ months (range 3.0+/12.8). Six patients showed no change (25%) with a median duration of 4.0 months 11 patients progressed (46%). A subjective improvemernt in tumor-related symptoms was reported by all responding patients and in 3 patients with no change. Most patients (7/10) with symptomatic bone lesions had a subjective improvement with reduction in analgesic drugs consumption. Objective responses were observed at all sites of disease. In fact, responses were seen in the skin liver lung bore and rodal metastases. The median overall survival was 13.0+ months (range 4.0/16.2+). Over a total of 160 cycles (a mean of 6.6 cycles/patient) grade 1-2 leukopenia was seen in 9 patients (37%) grade 1 thrombocytoperia in 4 patients (17%) and grade 1 anemia in only 2 cases (8%). Grade 3-4 leukopenia or thrombocytopenia were not seen. Phlebitis at the injection vein occurred in 3/10 patients (30%) which refuded to implant a central line. In patients with a central line or a port-a-cath no cases of vascula toxicity were seen. Gastrointestinal toxicity was very mild with 9 patients (37%) suffering from grade 1- 2 nausea/vomiting 6 patients (25%) complaining of grade 1-2 diarrhea and 6 patients with grade 1-2 stomatitis. Hand-foot syndrome was observed in only 1 patient. No cases of grade 3-4 gastrointestinal toxicities have been, observed No cases of cardiotoxicity and/or neurotoxicity were recorded The combination of high-dose FA and 5FU given as 48 hour continuous venous infusion every 2 weeks is active, at least in. terms of objective response rate and tumor related symptoms palliation against anthracycline-refractory MBC These results compare favorably with bolus administration of FA and 5FU or other salvage regimens.
引用
收藏
页码:2289 / 2292
页数:4
相关论文
共 50 条
  • [21] CONTINUOUS-INFUSION OF 5-FLUOROURACIL IN METASTATIC COLORECTAL-CANCER PATIENTS
    DEGRAEFF, A
    VANDEWOUW, AJ
    VANDEVEN, PJG
    TJIA, PF
    WITTEVEEN, PO
    NEIJT, JP
    ZONNENBERG, BA
    VENDRIK, CPJ
    NORTIER, JWR
    BLIJHAM, GH
    CANCER JOURNAL - FRANCE, 1993, 6 (03): : 159 - 162
  • [22] TREATMENT OF PATIENTS WITH METASTATIC GASTRIC-CANCER BY CONTINUOUS-INFUSION OF 5-FLUOROURACIL, CISPLATIN AND ETOPOSIDE
    IISHI, H
    TATSUTA, M
    TSUTSUI, S
    KITAMURA, S
    NAGASAWA, Y
    OKUDA, S
    ONCOLOGY REPORTS, 1994, 1 (01) : 47 - 52
  • [23] Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer
    deGramont, A
    Vignoud, J
    Tournigand, C
    Louvet, C
    Andre, T
    Varette, C
    Raymond, E
    Moreau, S
    LeBail, N
    Krulik, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (02) : 214 - 219
  • [24] FOLINIC ACID, 5-FLUOROURACIL BOLUS AND INFUSION AND MITOXANTRONE WITH OR WITHOUT CYCLOPHOSPHAMIDE IN METASTATIC BREAST-CANCER
    LOUVET, C
    DEGRAMONT, A
    DEMUYNCK, B
    BEERBLOCK, K
    VARETTE, C
    SOUBRANE, D
    MARPEAU, L
    PIGNE, A
    GUILLOT, T
    KRULIK, M
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (13) : 1835 - 1838
  • [25] CONTINUOUS INFUSION OF 5-FLUOROURACIL IN OVARIAN-CANCER PATIENTS REFRACTORY TO CISPLATIN AND CARBOPLATIN
    DEGRAEFF, A
    VANHOEF, MEHM
    TJIA, P
    HEINTZ, APM
    NEIJT, JP
    ANNALS OF ONCOLOGY, 1991, 2 (09) : 691 - 692
  • [26] Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin
    Nieto, Y
    Martín, M
    Alonso, JL
    Casado, A
    Ayala, F
    López-Martín, JA
    Rodríguez-Lescure, A
    Díaz-Rubio, E
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 50 (02) : 167 - 174
  • [27] Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin
    Yago Nieto
    Miguel Martín
    José Luis Alonso
    Antonio Casado
    Francisco Ayala
    José Antonio López-Martín
    Alvaro Rodríguez-Lescure
    Eduardo Díaz-Rubio
    Breast Cancer Research and Treatment, 1998, 50 : 167 - 174
  • [28] Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients:: A phase II study
    Nolè, F
    Munzone, E
    Mandalà, M
    Catania, C
    Orlando, L
    Zampino, MG
    Minchella, I
    Colleoni, M
    Peruzzotti, G
    Marrocco, E
    Goldhirsch, A
    ANNALS OF ONCOLOGY, 2001, 12 (01) : 95 - 100
  • [29] EXPERIENCE WITH 5-FLUOROURACIL IN METASTATIC CANCER OF THE BREAST
    DEMAREE, EW
    SHARP, GS
    CANCER CHEMOTHERAPY REPORTS, 1962, (25): : 95 - 96
  • [30] Treatment of metastatic breast cancer with continuous infusional 5 fluorouracil
    Karapetis, CS
    Patterson, WK
    Pittman, KB
    Kotasek, D
    Sage, RE
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1999, 29 (04): : 517 - 522